Selecting lactose for a capsule-based dry powder inhaler

Pharmaceutical Technology Europe

Volumn 16, Issue 4, 2004, Pages 23-35

  Steckel, Hartwig ^a   Borowski, Malte ^a   Eskandar, Fadi ^a   Villax, Peter ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA LACTOSE; BUDESONIDE; INHALAC 120; INHALAC 70; LACTOHALE 100; LACTOHALE 200; LACTOSE; PHARMATOSE 110; PHARMATOSE 325; SALBUTAMOL;

AEROSOL; ARTICLE; DRUG CAPSULE; DRUG DELIVERY SYSTEM; DRUG DOSE; DRUG FORMULATION; DRUG SCREENING; DRY POWDER; EQUIPMENT DESIGN; PARTICLE SIZE; PHYSICAL CHEMISTRY; POWDER INHALER; QUALITY CONTROL;

EID: 2342518794     PISSN: 01646826     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. I.J. Smith and M. Parry-Billings. "The Inhalers of the Future? A Review of Dry Powder Devices on the Market Today." Pulmonary Pharmacol. Ther. 16, 79-95 (2003).
2. H. te Wierik and P. Diepenmaat. "Formulation of Lactose for Inhaled Delivery Systems," Pharm. Technol. Eur. 14(11), 47-52 (2002 ).
3. N.Y.K. Chew and H.K. Chan, "Influence of Particle Size, Air Flow and Inhaler Device on the Dispersion of Mannitol Powders as Aerosols," Pharm. Res. 16 1098-1103 (1999).
4. M. Vidgren et al., "Effect of Powder Inhaler Design on Drug Deposition in the Respiratory Tract," Int. J. Pharm. 42, 211-216 (1988).
5. H. Steckel, "Inhalation Powders - A Simple Dosage Form for Pulmonary Delivery?" Swiss Pharma. 9a, 15-28 (2002).
6. Section 2.9.18, European Pharmacopoeia, 4th Edition (EDQM, 226 avenue de Colmar BP 207, F-67029 Strasbourg, France, 2002).
7. www.fda.gov/cder/guidance/2180dft.pdf
8. J.N. Staniforth, "Improvement in Dry Powder Inhaler Performance: Surface Passivation Effects," Aerosol Sci. Technol. 22(4), 346-353 (1995).